TY  - JOUR
AU  - Marin-Bañasco, C
AU  - Benabdellah, K
AU  - Melero-Jerez, C
AU  - Oliver, B
AU  - Pinto-Medel, M J
AU  - Hurtado-Guerrero, I
AU  - de-Castro, F
AU  - Clemente, D
AU  - Fernandez, O
AU  - Martin, F
AU  - Leyva, L
AU  - Suardiaz, M
PY  - 2017
DO  - 10.1111/bph.13674
UR  - http://hdl.handle.net/10668/10631
T2  - British journal of pharmacology
AB  - Recombinant IFN-ß is one of the first-line treatments in multiple sclerosis (MS), despite its lack of efficacy in some patients. In this context, mesenchymal stem cells (MSCs) represent a promising therapeutic alternative due to their immunomodulatory...
LA  - en
PB  - John Wiley & Sons
KW  - Mesenchymal Stem Cells
KW  - Mice, Inbred C57BL
KW  - Multiple Sclerosis, Chronic Progressive
KW  - Multiple Sclerosis, Relapsing-Remitting
KW  - Severity of Illness Index
KW  - Adipose Tissue
KW  - Animals
KW  - Disease Models, Animal
KW  - Encephalomyelitis, Autoimmune, Experimental
KW  - Female
KW  - Flow Cytometry
KW  - Genetic Therapy
KW  - Interferon-beta
KW  - Mesenchymal Stem Cell Transplantation
KW  - Mice
TI  - Gene therapy with mesenchymal stem cells expressing IFN-ß ameliorates neuroinflammation in experimental models of multiple sclerosis.
TY  - research article
VL  - 174
ER  -